Trials / Completed
CompletedNCT01543854
Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure
A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Hemodynamic Responses to Intravenous RLX030 Infusion in Subjects With Acute Heart Failure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 87 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the hemodynamic effect of RLX030 infusion in subjects with acute heart failure. In addition safety and effects on renal function and biomarkers will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RLX030 | Intravenous infusion of RLX030 over 20 hrs |
| DRUG | Placebo | Intravenous infusion of placebo over 20 hours |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-01-01
- Completion
- 2013-01-01
- First posted
- 2012-03-05
- Last updated
- 2014-08-05
Locations
20 sites across 6 countries: Argentina, Germany, Italy, Netherlands, Poland, Russia
Source: ClinicalTrials.gov record NCT01543854. Inclusion in this directory is not an endorsement.